PTC Therapeutics wins Russian approval for Translarna for nmDMD
US-based PTC Therapeutics has secured marketing approval in Russia for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The approval for ... Read More